Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update
Diagnostics · 30.01.2024 · 14 (3) · 296
DOI: 10.3390/diagnostics14030296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 30.01.2024. Verfasst von Radu Gabriel Vătășescu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Clinic Emergency Hospital, 014461 Bucharest, Romania. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Wolf–Parkinson–White (WPW) syndrome is a disorder characterized by the presence of at least one accessory pathway (AP) that can predispose people to atrial/ventricular tachyarrhythmias and even sudden cardiac death. It is the second most common cause of paroxysmal supraventricular tachycardia in most parts of the world, affecting about 0.1–0.3% of the general population. Most patients with WPW syndrome have normal anatomy, but it may be associated with concomitant congenital heart disease or systemic diseases. Although many individuals are asymptomatic, during supraventricular arrhythmia episodes, they may experience severe symptoms, including syncope or even sudden cardiac death (mainly due to pre-excited atrial fibrillation over rapidly conducting AP). In addition to arrhythmia-related symptoms, for some specific locations of the APs with overt anterograde conduction, there might be a reduction in exercise capacity mediated by a reduction in LV systolic performance due to anomalous LV depolarization. Although it is typically diagnosed through electrocardiography (ECG), additional tests are necessary for risk assessment. Management of WPW syndrome may be quite challenging and can vary from only acknowledging the presence of the accessory pathway to pharmacological treatment or radiofrequency ablation. Early diagnosis, risk assessment, and appropriate treatment are critical steps in the management of WPW syndrome, aiming to improve the quality of life and reduce the risk of life-threatening arrhythmias.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Clinic Emergency Hospital, 014461 Bucharest, Romania.
- 4th Department-Cardio-Thoracic Pathology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
- Emergency Institute for Cardiovascular Disease and Transplantation, 540136 Tirgu Mures, Romania.
- 8th Department-"Mother and Child", University of Medicine and Pharmacy "Iuliu Hațieganu", 400012 Cluj-Napoca, Romania.
- 2nd Pediatric Department, Clinical Children Hospital, 400177 Cluj-Napoca, Romania.
- Department of Pediatrics, Faculty of Medicine, "Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
ORCID-Profile: Radu Gabriel Vătășescu, Ioana Șuș, Ștefana María Moisa, Eliza Elena Cinteză
Zitieren
APA
Vătășescu, R. G., Paja, C. S., Șuș, I., Cainap, S., Moisa, Ș. M., & Cinteză, E. E. (2024). Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update. Diagnostics, 14(3), 296. https://doi.org/10.3390/diagnostics14030296
Vancouver
Vătășescu RG, Paja CS, Șuș I, Cainap S, Moisa ȘM, Cinteză EE. Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update. Diagnostics. 2024;14(3):296. doi:10.3390/diagnostics14030296
BibTeX
@article{Vtescu2024,
author = {Vătășescu, Radu Gabriel and Paja, Cosmina Steliana and Șuș, Ioana and Cainap, Simona and Moisa, Ștefana María and Cinteză, Eliza Elena},
title = {Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {3},
pages = {296},
doi = {10.3390/diagnostics14030296}
}
EUVIMED